Palbociclib In Progressive Brain Metastases

• Status: Recruiting
• Trial end date: 2025-09-01

Summary

This research study is studying palbociclib as a possible treatment for recurrent brain metastases.

• Pfizer, a pharmaceutical company, is supporting this research study by providing the study drug as well as funding for research activities

• Phase: Phase 2

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Pfizer
• Treatments: Palbociclib